CY1124236T1 - Διαλυμα εγχυσης λεβοντοπα - Google Patents
Διαλυμα εγχυσης λεβοντοπαInfo
- Publication number
- CY1124236T1 CY1124236T1 CY20211100353T CY211100353T CY1124236T1 CY 1124236 T1 CY1124236 T1 CY 1124236T1 CY 20211100353 T CY20211100353 T CY 20211100353T CY 211100353 T CY211100353 T CY 211100353T CY 1124236 T1 CY1124236 T1 CY 1124236T1
- Authority
- CY
- Cyprus
- Prior art keywords
- solution
- aqueous
- cns
- nervous system
- central nervous
- Prior art date
Links
- 239000000243 solution Substances 0.000 title abstract 7
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 6
- 239000011550 stock solution Substances 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 2
- 239000012062 aqueous buffer Substances 0.000 abstract 2
- 229960004502 levodopa Drugs 0.000 abstract 2
- 239000007853 buffer solution Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003186 pharmaceutical solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
Η εφεύρεση παρέχει υδατικό φαρμακευτικό διάλυμα για χρήση στη θεραπεία ασθενειών του κεντρικού νευρικού συστήματος (ΚΝΣ), το δε διάλυμα περιλαμβάνει τουλάχιστον 5 χλστγρ./κ.εκ. διαλελυμένο λεβοντόπα, και έχει pΗ στην περιοχή 3,0 έως 8Τ5. Το εν λόγω διάλυμα παρέχεται με ανάμιξη a) υδατικού διαλύματος αποθέματος που περιλαμβάνει λεβοντόπα, το εν λόγω δε διάλυμα αποθέματος έχει pΗ μικρότερο από 2,8 στους 25 °C και b) υδατικού ρυθμιστικού διαλύματος, για αύξηση του pΗ του εν λόγω διαλύματος αποθέματος, το εν λόγω δε ρυθμιστικό διάλυμα έχει pΗ τουλάχιστον 4,0 στους 25 °C. To υδατικό φαρμακευτικό διάλυμα χορηγείται σε ένα υποκείμενο που υποφέρει από ασθένεια του κεντρικού νευρικού συστήματος (ΚΝΣ) βραχέως μετά την ανάμιξη του υδατικού διαλύματος αποθέματος και του υδατικού ρυθμιστικού διαλύματος. Περαιτέρω, η εφεύρεση παρέχει ένα κιτ για χορήγηση υδατικών φαρμακευτικών διαλυμάτων σε υποκείμενα που υποφέρουν από ασθένειες του κεντρικού νευρικού συστήματος (ΚΝΣ).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1750707 | 2017-06-05 | ||
| PCT/EP2018/064774 WO2018224501A1 (en) | 2017-06-05 | 2018-06-05 | Levodopa infusion solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124236T1 true CY1124236T1 (el) | 2022-07-22 |
Family
ID=62567647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100353T CY1124236T1 (el) | 2017-06-05 | 2021-04-23 | Διαλυμα εγχυσης λεβοντοπα |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11633353B2 (el) |
| EP (3) | EP3838263A1 (el) |
| JP (2) | JP7134228B2 (el) |
| KR (1) | KR102437003B1 (el) |
| CN (1) | CN110753538A (el) |
| AR (1) | AR112070A1 (el) |
| AU (1) | AU2018280745B2 (el) |
| BR (1) | BR112019025215A2 (el) |
| CA (1) | CA3065990A1 (el) |
| CY (1) | CY1124236T1 (el) |
| DK (1) | DK3634384T3 (el) |
| EA (1) | EA201992685A1 (el) |
| ES (1) | ES2866981T3 (el) |
| HR (1) | HRP20210599T1 (el) |
| HU (1) | HUE054268T2 (el) |
| IL (1) | IL271169B (el) |
| LT (1) | LT3634384T (el) |
| MX (1) | MX2019014675A (el) |
| PL (1) | PL3634384T3 (el) |
| PT (1) | PT3634384T (el) |
| RS (1) | RS61749B1 (el) |
| SI (1) | SI3634384T1 (el) |
| TW (1) | TW201902463A (el) |
| WO (1) | WO2018224501A1 (el) |
| ZA (1) | ZA201908027B (el) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018224501A1 (en) * | 2017-06-05 | 2018-12-13 | Dizlin Pharmaceuticals Ab | Levodopa infusion solution |
| HUP2100456A1 (hu) * | 2021-12-28 | 2023-08-28 | Semmelweis Egyetem | Szemcsepp készítmény |
| EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54105221A (en) | 1978-02-02 | 1979-08-18 | Sankyo Co Ltd | Preparation of stable concentrated dopa injection |
| SE512655C2 (sv) | 1993-11-17 | 2000-04-17 | Medmera Sweden Hb C O Nil Dizd | Infusionslösning för medicinskt bruk innehållande L-dopa |
| DE19757224A1 (de) | 1997-12-22 | 1999-07-01 | Bayer Ag | Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation |
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| CN1845728B (zh) | 2003-08-29 | 2013-06-19 | 转化医药公司 | 包含左旋多巴和卡比多巴的药物组合物 |
| US20050070608A1 (en) | 2003-08-29 | 2005-03-31 | Julius Remenar | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| MX364974B (es) | 2009-05-19 | 2019-05-16 | Neuroderm Ltd | Composiciones para la administracion continua de inhibidores de dopa descarboxilasa. |
| AU2011101361A4 (en) | 2010-11-15 | 2011-12-15 | Andrew Lumsden | A prefilled syringe for administering buffered lignocaine |
| ES2776734T3 (es) | 2010-11-15 | 2020-07-31 | Neuroderm Ltd | Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello |
| CN102755252A (zh) | 2011-07-28 | 2012-10-31 | 辽宁海思科制药有限公司 | 一种新的包装氨基酸葡萄糖注射液的双室输液袋 |
| CA2904838C (en) * | 2013-03-13 | 2021-03-16 | Neuroderm Ltd. | Method for treatment of parkinson's disease |
| WO2015034870A2 (en) | 2013-09-03 | 2015-03-12 | Arocha Max | Double-chamber mixing syringe and method of use |
| WO2018224501A1 (en) * | 2017-06-05 | 2018-12-13 | Dizlin Pharmaceuticals Ab | Levodopa infusion solution |
-
2018
- 2018-06-05 WO PCT/EP2018/064774 patent/WO2018224501A1/en active Search and Examination
- 2018-06-05 SI SI201830257T patent/SI3634384T1/sl unknown
- 2018-06-05 AR ARP180101500A patent/AR112070A1/es unknown
- 2018-06-05 LT LTEP18730319.3T patent/LT3634384T/lt unknown
- 2018-06-05 EP EP21153018.3A patent/EP3838263A1/en active Pending
- 2018-06-05 TW TW107119351A patent/TW201902463A/zh unknown
- 2018-06-05 AU AU2018280745A patent/AU2018280745B2/en active Active
- 2018-06-05 EA EA201992685A patent/EA201992685A1/ru unknown
- 2018-06-05 CN CN201880037143.6A patent/CN110753538A/zh active Pending
- 2018-06-05 US US16/619,176 patent/US11633353B2/en active Active
- 2018-06-05 EP EP24183451.4A patent/EP4445953A2/en active Pending
- 2018-06-05 PL PL18730319T patent/PL3634384T3/pl unknown
- 2018-06-05 DK DK18730319.3T patent/DK3634384T3/da active
- 2018-06-05 RS RS20210467A patent/RS61749B1/sr unknown
- 2018-06-05 KR KR1020197037906A patent/KR102437003B1/ko active IP Right Grant
- 2018-06-05 HU HUE18730319A patent/HUE054268T2/hu unknown
- 2018-06-05 PT PT187303193T patent/PT3634384T/pt unknown
- 2018-06-05 IL IL271169A patent/IL271169B/en unknown
- 2018-06-05 CA CA3065990A patent/CA3065990A1/en active Pending
- 2018-06-05 JP JP2020516960A patent/JP7134228B2/ja active Active
- 2018-06-05 ES ES18730319T patent/ES2866981T3/es active Active
- 2018-06-05 BR BR112019025215-0A patent/BR112019025215A2/pt unknown
- 2018-06-05 EP EP18730319.3A patent/EP3634384B1/en active Active
- 2018-06-05 MX MX2019014675A patent/MX2019014675A/es unknown
-
2019
- 2019-12-03 ZA ZA2019/08027A patent/ZA201908027B/en unknown
-
2021
- 2021-04-15 HR HRP20210599TT patent/HRP20210599T1/hr unknown
- 2021-04-23 CY CY20211100353T patent/CY1124236T1/el unknown
-
2022
- 2022-06-29 JP JP2022104764A patent/JP7437450B2/ja active Active
-
2023
- 2023-02-28 US US18/175,599 patent/US12048764B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124236T1 (el) | Διαλυμα εγχυσης λεβοντοπα | |
| Lieberman et al. | A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| RU2470642C2 (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
| EA201991316A1 (ru) | Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| CY1106430T1 (el) | Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο | |
| BR112023006337A2 (pt) | Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| AR117614A1 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
| EA202190334A1 (ru) | Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением | |
| BR112021023110A2 (pt) | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton | |
| CO2021000450A2 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
| FI3672631T3 (fi) | Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia | |
| BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
| BR112019002655A2 (pt) | composto, intermediário de síntese, uso e composição farmacêutica neuromoduladora | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| BR112017025527A2 (pt) | preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe. | |
| EA201990668A1 (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| BR112021022503A2 (pt) | Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| MX2024005430A (es) | Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. |